Salbutamol is a selective beta2-adrenoceptor agonist. At therapeutic doses, it acts on the beta2-adrenoceptors of bronchial muscle, with little or no action on the heart. With its fast onset of action, it is particularly suitable for the management and prevention of attack in asthma.
Increasing use of beta2-agonists may be a sign of worsening asthma. Under these conditions, a reassessment of the patient’s therapy plan may be required and concomitant glucocorticosteroid therapy should be considered.